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otterdam, the Netherlands
hronic total coronary occlusions (CTOs) are a significant
linical problem and are observed in up to 30% to 35% of
atients with suspected or known coronary artery disease
ho undergo diagnostic coronary artery catheterization (1).
ecause the success rate of percutaneous coronary interven-
ion (PCI) is lower than for nonocclusive stenosis, the
ajority of these patients are frequently sent for surgery. In
he multivessel PCI versus coronary artery bypass graft
urgery (CABG) SYNTAX (SYNergy Between PCI with
AXUS and Cardiac Surgery) study, the prevalence of
TO in the randomized arm was only 10%, but in the
ABG registry arm it was 40%. In case of single-vessel
isease, CTO patients may not be revascularized at all and
ontinued on medical treatment. Although percutaneous
reatment of CTOs is a challenging task with a serious risk
f vessel perforation, the conservative management of a
TO may not be the best option. Several observational
See page 44
tudies have shown a survival benefit if a CTO is success-
ully treated versus the vessel not being opened (2–4). This
ay be because during successive years, patients are partially
rotected against subsequent events in the remaining open
essels. Also, improvement in regional and global left
entricular function provided by treatment has been shown
ith a decrease in end-systolic volume and an increase in
jection fraction (5,6), which are, in general, related to
ositive long-term survival. On the other hand, the recently
ublished randomized TOSCA-2 (Total Occlusion Study
f Canada) study showed no improvement in left ventricular
jection fraction and remodeling in patients who underwent
CI of the total occluded infarct-related vessel shortly after
cute myocardial infarction (MI) compared with optimal
edical therapy (7).
Editorials published in the JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-C
ions or the American College of Cardiology.
From the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.The big difference between the TOSCA-2 trial and the
onrandomized trials is the method of patient selection. In
he TOSCA-2 trial, patients were included shortly after an
cute MI for which no primary PCI was performed. In
ddition, thrombolytic agents were only administrated in
0% of patients. Therefore, the study included relatively
arge infarctions with probably a small amount of viable
issue. In contrast, the nonrandomized trials frequently
ncluded patients with anginal complaints who usually had
positive ischemia stress test indicating a significant
mount of viable tissue. As was shown in 2006, the amount
f viable tissue in the CTO region (as detected by delayed
ontrast-enhanced magnetic resonance imaging [MRI]) is
elated to reversed left ventricular remodeling during
ollow-up (8). Hence, pre-procedural viability testing seems
o be eminently important in making the decision for or
gainst invasive treatment.
In this issue of JACC: Cardiovascular Interventions,
heng et al. (9) confirmed the 2006 findings regarding
iability testing and also studied the recovery of regional
unction in greater detail. In addition to regional wall
hickening and viability, they investigated myocardial blood
ow (MBF) using a quantitative first-pass MRI perfusion
echnique. In this technique, quantitative MBF is derived
rom a first pass of an intravenous injection of an MRI
ontrast agent through the myocardium using a deconvolu-
ion method on the successive image intensities. The inves-
igators have a long experience with this technique, which
hey have validated extensively in animal and human stud-
es. In the hands of these experts, it is as reliable as positron
mission tomography imaging, with the advantage of a
igher spatial resolution. They clearly showed that, before
reatment, hyperemic myocardial blood flow both in the
TO area and in the area from nonoccluded lesions is
educed and becomes normalized within 24 h after the
rocedure. In this small number of patients, the data give
he impression that improvement of wall thickening takes a
onger time, although this is statically inconclusive. More
emarkable is the increase in resting wall thickening without
mprovement in resting MBF. The question is whether
hese areas at baseline represent more chronic stunning
nstead of hibernation. This also raises the question of
hether there was a relationship between improvement in
BF and regional wall thickening. The results of this study
hould be considered in the perspective of the low sample
ize and baseline differences between the groups (especially
he larger amount of scar tissue in the medically treated
TO group). It is unclear whether this could also explain
he low baseline MBF in the stenotic but not occluded
reas.
What are the consequences of this study? Pre-procedural
valuation with delayed contrast-enhanced MRI may help
n determining which patients may benefit from PCI of a
TO. Perfusion imaging was not evaluated as a diagnostic
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Editorial Comment
55ool in this study and will probably not be routinely
erformed because of the cumbersome acquisition and
nalysis, but it can give us insight into the recovery process
f the myocardium after recanalization.
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